Aclaris Therapeutics (ACRS) Assets (2014 - 2026)

Aclaris Therapeutics' Assets history runs 13 years deep, the most recent figure standing at $198.7 million for Q1 2026.

• On a quarterly basis, Assets changed 0.32% year-over-year to $198.7 million in Q1 2026; TTM through Mar 2026 was $198.7 million, a 0.32% change from a year earlier, with the FY2025 full-year figure at $160.5 million, down 27.17% from the prior year.
• Assets improved to $198.7 million in Q1 2026 per ACRS's latest filing, from $160.5 million in the prior quarter.
• Across five years, Assets topped out at $278.0 million in Q2 2022 and bottomed at $160.5 million in Q4 2025.
• The 5-year median for Assets is $198.7 million (2026), against an average of $209.9 million.
• Across the five-year window, Assets soared 40.35% in 2022 and tumbled 31.65% in 2024, its largest moves.
• Year by year, Assets stood at $254.6 million in 2022, then dropped by 22.46% to $197.4 million in 2023, then advanced by 11.61% to $220.3 million in 2024, then dropped by 27.17% to $160.5 million in 2025, then increased by 23.84% to $198.7 million in 2026.
• Per Business Quant, the three latest ACRS Assets figures stand at $198.7 million (Q1 2026), $160.5 million (Q4 2025), and $175.5 million (Q3 2025).